Trials / Completed
CompletedNCT01920633
A Screening Protocol to Assess Adults and Adolescents With Down Syndrome for Eligibility For Upcoming Study of RG1662 (Study BP27832)
A Screening Protocol to Assess Adult and Adolescent Individuals With Down Syndrome for Eligibility to Participate in an Upcoming Study to Evaluate the Efficacy, Safety and Tolerability of RG1662 (Study BP27832)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 135 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 12 Years – 30 Years
- Healthy volunteers
- Not accepted
Summary
This is a single visit study in which people with Down syndrome aged 12-30 will attend the clinical center to undergo assessments to evaluate their eligibility for potential enrollment in the future BP27832 Phase II clinical study which will evaluate the efficacy, safety and tolerability of RG1662. Study participants may withdraw from this study at any time and for any reason.
Conditions
Timeline
- Start date
- 2013-10-31
- Primary completion
- 2015-01-31
- Completion
- 2015-01-31
- First posted
- 2013-08-12
- Last updated
- 2017-07-19
Locations
22 sites across 7 countries: United States, Argentina, Canada, Mexico, New Zealand, Singapore, Spain
Source: ClinicalTrials.gov record NCT01920633. Inclusion in this directory is not an endorsement.